Medical Conditions and Demographic, Service and Clinical Factors Associated with Atypical Antipsychotic Medication Use Among Children with An Autism Spectrum Disorder.

The team mailed short surveys to families of children with autism. They asked if the child takes any atypical antipsychotics such as risperidone or aripiprazole.

Parents also checked boxes for age, other medicines, and medical problems. The answers gave a snapshot of who gets these drugs in the United States.

Among kids aged 2–11, about 5 percent were on an antipsychotic. The rate jumped to 18 percent for teens aged 12–17.

Older age and mixing several psychotropics went hand-in-hand with antipsychotic use.

Hudson et al. (2012) reviewed 33 drug trials and remind us that only two antipsychotics have strong evidence for autism. Their paper sits under the new survey like a safety label—prevalence is rising even though proof is thin.

Smith et al. (2010) saw the same climb six years earlier. Their national registry showed one in three kids with autism took some psychotropic. Deserno et al. (2017) narrow the lens to antipsychotics and still find the same age jump, so the trend is holding.

Memari et al. (2012) looked at Iranian pupils and found an eye-popping 80 percent on psychotropics, mostly antipsychotics. The huge gap looks like a contradiction, but the Iranian sample came from specialized schools and had severe behavior problems. Same drug class, different severity filter.

You now have hard numbers to share with families at plan-of-care meetings. If a teen is already on two or more psychoactive drugs, pause and ask why each pill is there. Use the Hudson et al. (2012) review to steer the talk toward evidence-based choices and side-effect checks.